Drugs / Vimseltinib
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ROMVIMZA | — | 2026-06-26 | fda.gov ↗ |
| Approved | EU (EMA) | Romvimza | — | 2025-09-17 | europa.eu ↗ |
| Approved | US (FDA) | ROMVIMZA | — | 2025-02-14 | fda.gov ↗ |
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07539090 | Jun → Aug 2026 overdue | — | Deciphera Pharmaceuticals, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT07158411 | Nov 2025 → Jan 2026 | — | Deciphera Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1 | NCT07158398 | Oct → Dec 2025 | — | Deciphera Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04242238 | Jan 2020 → Aug 2025 | dedifferentiated liposarcoma, leiomyosarcoma, myxofibrosarcoma, undifferentiated pleomorphic sarcoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03069469 | Feb 2017 → Aug 2028 expected | cancer, tenosynovial giant cell tumor, diffuse type | Deciphera Pharmaceuticals, LLC | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06619561 | Nov 2024 → Oct 2029 expected | chronic graft versus host disease | Deciphera Pharmaceuticals, LLC | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05059262 | Oct 2021 → Aug 2023 overdue | tenosynovial giant cell tumor, diffuse type, tenosynovial giant cell tumor, localized type | Deciphera Pharmaceuticals, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vimseltinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07158398 ↗ |
| Known as | DCC-3014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04242238 ↗ |
| Known as | DP-6865 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095202 ↗ |
| Action | Inhibit | “CSF1R Inhibitor” NCT04242238 ↗ |
| Modality | Small molecule | “Vimseltinib is an oral switch-control tyrosine kinase inhibitor” PMID 37593881 ↗ Aug 2023 |
| Route | Oral | “DCC-3014 will be administered in pill form.” NCT04242238 ↗ |
| Target | CSF1R | “CSF1R Inhibitor” NCT04242238 ↗ |